[Interleukin-1 receptor antagonist-treatment of patients with type 2 diabetes] - PubMed (original) (raw)
. 2007 Nov 5;169(45):3868-71.
[Article in Danish]
Affiliations
- PMID: 18031661
[Interleukin-1 receptor antagonist-treatment of patients with type 2 diabetes]
[Article in Danish]
Claus Morten Larsen et al. Ugeskr Laeger. 2007.
Abstract
Interleukin-1 receptor antagonist (IL-1Ra) expression is reduced in islets of patients with type 2 diabetes. 70 patients with type 2 diabetes were randomized to treatment with anakinra (IL-1Ra) or placebo for 13 weeks. Following treatment glycated hemoglobin was 0.46 percent lower, C-peptide secretion was enhanced, and systemic IL-6 and C-reactive protein levels were reduced in the anakinra group compared to the placebo group. Insulin resistance remained unchanged. Blocking IL-1 activity improved glycemia and b-cell secretory function and reduced markers of systemic inflammation.
Republished from
- Interleukin-1-receptor antagonist in type 2 diabetes mellitus.
Larsen CM, Faulenbach M, Vaag A, Vølund A, Ehses JA, Seifert B, Mandrup-Poulsen T, Donath MY. Larsen CM, et al. N Engl J Med. 2007 Apr 12;356(15):1517-26. doi: 10.1056/NEJMoa065213. N Engl J Med. 2007. PMID: 17429083 Clinical Trial.
Publication types
LinkOut - more resources
Research Materials